Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
46
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Dec 5, 2024
0
7
CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine.
Jul 18, 2024
0
13
A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive form it takes in some ...
Mar 28, 2024
0
13
A study by researchers at Columbia and the Hong Kong University of Science and Technology is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development ...
Dec 18, 2023
0
29
Researchers have come one step closer to answering why, in some patients, a type of lymphoma changes from indolent to aggressive, and in particular, they are closer to identifying which patients are at high risk of this change ...
Dec 12, 2023
0
4
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
0
Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.
Nov 21, 2023
0
1
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. ...
Oct 24, 2022
0
5
Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, capture-based, next-generation sequencing (NGS) panel, ...
Jul 29, 2021
0
0
Follicular lymphoma is the most common of the indolent non-Hodgkin's lymphomas, and the second-most-common form of non-Hodgkin's lymphomas overall. It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a partially follicular pattern. It is positive for the B-cell markers CD10, CD19, CD20, and CD22 but almost always negative for CD5.
There are several synonymous and obsolete terms for this disease, such as CB/CC lymphoma (Centroblastic and Centrocytic lymphoma), nodular lymphoma and Brill-Symmers Disease.
This text uses material from Wikipedia licensed under CC BY-SA
